The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

Wednesday, May 09, 2012

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series09:30 EDT Wednesday, May 09, 2012TARRYTOWN, N.Y., May 9, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 11, 2012.  Conference call details are as follows: Live conference call (US):  (888) 889-1309 Live conference call (Outside the US):  (773) 756-0161 Passcode:  BIOTECH Replay (US):  (888) 568-0720  Replay (Outside the US):  (402) 998-1481  Passcode:  1017A recording of the call will be available for telephone replay until May 17, 2012.Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at Information:Michael Aberman, M.D.   Peter DworkinInvestor Relations Corporate Communications914.847.7799    peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.